Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The user is considering a second hair transplant or scalp micropigmentation to address thinning in the crown area and hide scars from a previous transplant. They have been using finasteride and minoxidil for three years but are concerned about the appearance of their donor area and the effectiveness of scalp micropigmentation.

The user shared progress pictures after 5 months of using 1mg finasteride, weekly 1.5mm microneedling, and daily 2mg copper peptide injections. They discussed their hair loss treatment and results.

A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.

PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.

A 21-year-old experiencing hair loss and depression is planning to start finasteride treatment and is asking for others' experiences. Another user responds positively, stating that finasteride has helped alleviate their depression caused by hair loss.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

A 37-year-old man treated his hair loss with 0.5mg finasteride every other day and 5% minoxidil twice daily for 5 months, reducing finasteride from 1mg due to side effects. His hair improved significantly, with positive changes visible from all angles, and he experienced no more side effects after the dosage adjustment.

There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.

Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).

A 19-year-old male has been using topical finasteride and minoxidil for 8 months with no progress and is considering seeking a second opinion due to potential misdiagnosis. The discussion revolves around whether the hair loss is due to male pattern baldness, alopecia areata, or a vitamin deficiency.

The user switched from Hims topical finasteride and minoxidil to Musely Hair Pill Bloom+, which includes minoxidil, dutasteride, and other vitamins, and noticed new hair growth but also experienced lower blood pressure. Another user ordered a minoxidil-only pill.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Update on HMI-115 clinical trial expected in July or August.

The conversation discusses experiences with NMN supplementation for hair growth, with some users reporting increased hair growth activity and others seeing no significant changes. OP has been using dutasteride and oral minoxidil, and recently added NMN, noticing increased shedding, which they hope indicates new hair growth.

User 74775446 shares successful hair regrowth results using dermaroller/pen and minoxidil. Others discuss their experiences and concerns about finasteride side effects.

A 48-year-old man's 11-month progress using 1mg finasteride for hair loss treatment, with significant improvement and no side effects. Other users share their experiences, with some also seeing positive results, while others have not been as successful.

The user achieved impressive hair regrowth using 1mg finasteride and topical minoxidil, and is now adding dutasteride due to recent diffuse thinning. They experienced initial side effects with finasteride but no longer have issues.

The user is considering using P5P to reduce high prolactin levels and is questioning if oral minoxidil could be contributing to the issue. They are also debating whether to switch from oral to topical minoxidil.

PP405 shows significantly better early-stage hair regrowth results compared to minoxidil and finasteride, with 31% of users experiencing over 20% density increase in 4–8 weeks. Minoxidil and finasteride show minimal or no visible regrowth in the same timeframe.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

The user is seeking recommendations for a knowledgeable dermatologist in the Denver/Boulder area to address male pattern baldness, as they are dissatisfied with their current treatment of topical finasteride and are considering switching to dutasteride. They feel their current doctor is not open to exploring different treatments that could improve hairline thickness.

Hair loss treatments, specifically the use of finasteride, microneedling and potentially oral minoxidil. People discussed their experiences with finasteride, its effects on sexual behaviors, as well as potential solutions such as tadalafil or using other growth factor signal peptides for hope in curing male pattern baldness.

Different minoxidil formulations affect hair growth and side effects. Higher propylene glycol and pH levels improve effectiveness but can cause scalp irritation.

A user shared their positive 3-month results using a treatment for hair loss that includes Dermaroller, Minoxidil, and Amplexe Shampoo. They avoided using finasteride due to its risks.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.